Abstract
Imatinib induces a high complete cytogenetic response (CCR) rate in relapsed chronic myelogenous leukemia. By analyzing minimal residual disease (MRD) under the levels of CCR, we tried to assess the molecular response after imatinib therapy. By using real-time quantitative reverse transcriptase-polymerase chain reaction (Q-RT-PCR), MRD was evaluated in 23 patients (3 in cytogenetic relapse, 6 in chronic phase, 9 in accelerated phase, and 5 in blast crisis) who were treated with standard-dose imatinib for relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation. With a median therapy time of 399 days (range, 35-817 days), 19 (83%) patients achieved a CCR. Meanwhile, 11 (58%) of them achieved a molecular remission (MR), which was associated with improved survival. The Q-RT-PCR data were compared according to the best response (MR, n = 11; CCR, n = 8) in the patients achieving a CCR. The BCR-ABL/ABL ratios were similar in 2 groups at 3 months but were significantly different at 6 months (median, 0.0000012 for MR and 0.00022 for CCR; P =.003). The probability of a subsequent MR was significantly higher in patients with a lower BCR-ABL/ABL ratio at 6 months (100% for <0.0001 versus 33% for >/=0.0001; P =.006)...Continue Reading
References
Oct 13, 1988·The New England Journal of Medicine·R KurzrockM Talpaz
Jan 1, 1993·Leukemia & Lymphoma·A GratwohlG Gahrton
Jun 19, 1998·Bone Marrow Transplantation·F van RheeJ M Goldman
Apr 29, 1999·The New England Journal of Medicine·C L Sawyers
Jun 9, 1999·Leukemia·C PreudhommeP Fenaux
Sep 14, 1999·Leukemia·M EderB Hertenstein
Nov 11, 1999·Leukemia·M EmigA Hochhaus
Dec 3, 1999·British Journal of Haematology·S BranfordZ Rudzki
Nov 13, 2001·Bone Marrow Transplantation·B WassmannO G Ottmann
Mar 1, 2002·The New England Journal of Medicine·Hagop KantarjianUNKNOWN International STI571 CML Study Group
Mar 2, 2002·European Journal of Haematology·J StentoftP Hokland
Mar 6, 2002·Blood·Moshe TalpazCharles L Sawyers
May 3, 2002·Blood·Eduardo OlavarriaJohn M Goldman
Jul 30, 2002·European Journal of Haematology·Yoo-Jin KimChun-Choo Kim
Aug 16, 2002·British Journal of Haematology·Lihui WangRichard E Clark
Aug 30, 2002·Leukemia·K MerxA Hochhaus
Sep 7, 2002·International Journal of Hematology·You Kyoung LeeDong-Wook Kim
Oct 24, 2002·Blood·Hagop M KantarjianJorge Cortes
Jan 17, 2003·Blood·Shaun R McCannMark Lawler
Feb 6, 2003·Cancer·Hagop M KantarjianMoshe Talpaz
Mar 15, 2003·Blood·Jorge CortesHagop Kantarjian
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Mar 22, 2003·British Journal of Haematology·Lihui WangRichard E Clark
Jun 5, 2003·Seminars in Hematology·Tim Hughes, Susan Branford
Jul 5, 2003·Blood·Seok LeeChun-Choo Kim
Jul 19, 2003·Blood·Feng LinJaspal Kaeda
Sep 13, 2003·Forensic Science International : Synergy·Yoo-Li KimDong-Wook Kim
Sep 13, 2003·Leukemia·P PaschkaA Hochhaus
Oct 8, 2003·The Keio Journal of Medicine·Andrew J UllmannThomas Fischer
Nov 25, 2003·Bone Marrow Transplantation·Y-J KimC-C Kim
Jan 13, 2004·Bone Marrow Transplantation·Y-J KimC-C Kim
Citations
May 2, 2009·Biochimica Et Biophysica Acta·Michael A Tainsky
Jun 24, 2016·The Korean Journal of Internal Medicine·Sung-Eun LeeDong-Wook Kim
Apr 27, 2021·Frontiers in Oncology·Yuqi GuanJianfeng Zhou
Jun 7, 2007·Archives of Pathology & Laboratory Medicine·Scott D DufresneGregory J Tsongalis